Detail akcie Onconetix Rg online

Business Summary: Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Onconetix Inc revenues decreased 72% to $512K. Net loss applicable to common stockholders decreased 28% to $21.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$4147.55 to -$56.44.